
BIOA Stock Forecast & Price Target
BIOA Analyst Ratings
Bulls say
Bioage Labs is well-positioned in the biopharmaceutical industry, with a focus on targeting molecular causes of aging and partnerships with major pharmaceutical companies. Their strong financial position, promising lead asset and potential for expansion, along with expected positive results from ongoing clinical trials, make them a promising investment opportunity. However, potential competition from companies like AC Immune SA and financing risks should also be considered.
Bears say
Bioage Labs is facing potential delays in the development and commercialization of BGE-102, as well as challenges in finding success with their current research and development pipeline. Additionally, their partnership with Roche may not materialize as expected, leading to a lack of funding and resources for future projects. Furthermore, the company's relatively new presence in the biotechnology industry and lack of a proven track record may make it a risky investment option.
This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares